Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PTX

Pernix Therapeutics (PTX) Stock Price, News & Analysis

Pernix Therapeutics logo

About Pernix Therapeutics Stock (NASDAQ:PTX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$0.21
52-Week Range
N/A
Volume
16,105 shs
Average Volume
3.04 million shs
Market Capitalization
$419 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pernix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTX Stock News Headlines

PANXD PTX Metals Inc.
Bicycle Therapeutics PLC ADR BCYC
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Prescient Therapeutics Ltd
Pernix Therapeutics Holdings Inc (PTX)
See More Headlines

PTX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI) and Argos Therapeutics (ARGSQ).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$146.07 million
Price / Cash Flow
N/A
Book Value
($14.77) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$419 thousand
Optionable
Optionable
Beta
1.20
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:PTX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners